Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders

European Journal of Human Genetics

Volumn 10, Issue 12, 2002, Pages 819-824

  van Rhijn, Bas W G ^a,b   van Tilborg, Angela A G ^a   Lurkin, Irene ^a   Bonaventure, Jacky ^c   de Vries, Annie ^a   Thiery, Jean Paul ^d   van der Kwast, Theodorus H ^a   Zwarthoff, Ellen C ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSTITUT CURIE   (France)

Author keywords

Achondroplasia; Bladder; Cancer; Fibroblast growth factor receptor 3 (FGFR 3); Hypochondroplasia; Mutation; SADDAN

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ACANTHOSIS NIGRICANS; ACHONDROPLASIA; ADULT; AGED; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BLADDER CANCER; BLADDER TUMOR; BONE DISEASE; CANCER RISK; CARCINOGENESIS; CHONDRODYSPLASIA; CODON; CONTROLLED STUDY; CRANIOFACIAL SYNOSTOSIS; FEMALE; GENE ACTIVATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SCREENING TEST; SOMATIC MUTATION; THANATOPHORIC DWARFISM; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BONE DISEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; URINARY BLADDER NEOPLASMS;

EID: 0036926992     PISSN: 10184813     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5200883     Document Type: Article

References (27)

1. Johnson DE, Williams LT: Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60: 1-41.
2. Robertson SC, Tynan JA, Donoghue DJ: RTK mutations and human syndromes: when good receptors turn bad. Trends Genet 2000; 16: 265-271.
3. Murgue M, Tsunekawa S, Rosenberg I, deBeaumont M, Podolsky DK: Identification of a novel variant of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium. Cancer Res 1994; 54: 5206-5211.
4. Delezoide AL, Benoist-Lasselin C, Legeai-Mallet L et al: Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification. Mech Dev 1998; 77: 19-30.
5. Cappellen D, De Oliveira C, Ricol D et al: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23: 18-20.
6. Passos-Bueno MR, Wilcox WR, Jabs EW, Sertié AL, Alonso LG, Kitoh H: Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat 1999; 14: 115-125.
7. Vajo Z, Francomano CA, Wilkin DJ: The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: The achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 2000; 21: 23-39.
8. Naski MC, Wang Q, Xu J, Ornitz DM: Graded activation of fibroblast growth receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 1996; 13: 233-237.
9. Webster MK, Donoghue DJ: FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 1997; 13: 178-182.
10. Tavormina PL, Shiang R, Thompson LM et al: Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 1995; 9: 321-328.
11. Bellus GA, Spector EB, Speiser PW et al: Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 2000; 67: 1411-1421.
12. Chesi M, Nardini E, Brents LA et al: Frequent translocation. t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260-264.
13. Richelda R, Ronchetti D, Baldini L et al: A novel translocation t(4;14)(p16.3;q32.3) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997; 90: 4062-4070.
14. Fracchiolla NS, Luminari S, Baldini L, Lombardi L, Maiolo AT, Neri A: FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma. Blood 1998; 92: 2987-2989.
15. Wu R, Connolly D, Ngelangel C, Bosch FX, Muñoz N, Cho KR: Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene 2000; 19: 5543-5546.
16. Billerey C, Chopin D, Aubriot-Lorton M-H et al: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001; 158: 1955-1959.
17. Van Rhijn BWG, Lurkin I, Radvanyi F, Kirkels WJ, Van der Kwast ThH, Zwarthoff EC: The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61: 1265-1268.
18. Sibley K, Cuthbert-Heavens D, Knowles MA: Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001; 20: 686-691.
19. Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW: Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet 1995; 11: 462-464.
20. Rousseau F. Bonaventure J, Legeai-Mallet L et al: Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1994; 371: 252-254.
21. Shiang R, Thompson LM, Zhu YZ et al: Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994; 787: 335-342.
22. Bellus GA, Hefferon TW, Ortiz de Luna RI et al: Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet 1995; 56: 368-373.
23. Tavormina PL, Bellus GA, Webster MK et al: A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet 1999; 64: 722-731.
24. Bellus GA, McIntosh I, Smith EA et al: A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 1995; 10: 357-359.
25. Kleinerman RA, Tarone RE, Abramson DH, Seddon JM, Li FP, Tucker MA: Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst 2000; 92: 2037-2039.
26. Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, Eto Y. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 2001; 92: 2555-2561.
27. Winterpacht A, Hilbert K, Stelzer C et al: A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia. Physiol Genomics 2000; 2: 9-12.